Supplementary Material – T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer

<strong>Figure S1. </strong>Patient disposition by TcellinfGEP score at data cutoff (July 30, 2018). <strong>Figure S2.</strong> Patient disposition by PD-L1 CPS status at data cutoff (July 30, 2018). <strong>Table S1. </strong>Baseline characteristics by TcellinfGEP score. <strong>Table S2.</strong> Baseline characteristics by PD-L1 CPS status. <strong>Table S3. </strong>Prevalence of TcellinfGEP and PD-L1 CPS. <strong>Table S4.</strong> Clinical utility profile for PD-L1 CPS.